FY2026 EPS Forecast for Immunic Decreased by Analyst

Immunic, Inc. (NASDAQ:IMUX – Free Report) – Analysts at Brookline Capital Markets decreased their FY2026 earnings estimates for shares of Immunic in a research note issued on Friday, November 13th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will post earnings of ($4.39) per share for the year, down from their previous forecast of ($3.86). The consensus estimate for Immunic’s current full-year earnings is ($3.81) per share. Brookline Capital Markets also issued estimates for Immunic’s Q4 2026 earnings at ($1.51) EPS.

Immunic (NASDAQ:IMUX – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20).

Other analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Immunic in a report on Wednesday. Ladenburg Thalmann & Co. Inc. upgraded Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Roth Capital restated a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Wall Street Zen lowered Immunic from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 14th. Finally, Zacks Research cut Immunic from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Immunic currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.71.

Get Our Latest Research Report on IMUX

Immunic Stock Down 1.6%

NASDAQ IMUX opened at $7.40 on Wednesday. The firm’s fifty day simple moving average is $8.29 and its two-hundred day simple moving average is $11.54. Immunic has a 12-month low of $5.06 and a 12-month high of $17.43.

Institutional Investors Weigh In On Immunic

A number of large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its holdings in shares of Immunic by 21.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company’s stock valued at $69,000 after buying an additional 1,400 shares during the last quarter. Alps Advisors Inc. increased its position in shares of Immunic by 28.0% in the 3rd quarter. Alps Advisors Inc. now owns 17,694 shares of the company’s stock valued at $165,000 after acquiring an additional 3,870 shares during the period. State Street Corp increased its position in shares of Immunic by 36.9% in the 3rd quarter. State Street Corp now owns 83,859 shares of the company’s stock valued at $780,000 after acquiring an additional 22,600 shares during the period. CTC Alternative Strategies Ltd. purchased a new position in Immunic in the 1st quarter worth $27,000. Finally, ADAR1 Capital Management LLC purchased a new position in Immunic in the 1st quarter worth $33,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic News Summary

Here’s some of the latest news about IMUX:

  • Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to a loss of $0.56 from a loss of $0.68, and its FY2027 estimate to a loss of $2.27 from $2.47. The firm maintained a Buy rating. MarketBeat analyst estimates
  • Neutral Sentiment: A report highlights Immunic’s approaching December multiple-sclerosis readout. Positive results could support the shares, while disappointing data could weigh on them; the article does not report results yet. Immunic Nears Multiple Sclerosis Readout
  • Negative Sentiment: Other forecast revisions point to continuing uncertainty around costs and losses: HC Wainwright slightly increased projected losses for FY2026, FY2028, and FY2029, while Brookline lowered its Q4 and FY2026 EPS estimates more substantially. These cuts may add pressure as investors assess Immunic’s funding needs and development progress. MarketBeat analyst estimates

Immunic Company Profile

(Get Free Report)

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.

Featured Articles

Earnings History and Estimates for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.